Outcomes 2019 - Baylor Scott & White Heart and Vascular Hospital BSWHHVH_646_2019 Outcomes JOOMAG MOD | Page 45

Over six million people a year live with heart failure, and only about 2,200 receive a new heart each year. Since 2014, the Heart-to-Heart Program at Baylor Dallas has been reminding patients of their great fortune by inviting them back to see and hold their former heart, while educating them on how to care for their new one. 50 (FY19) Hosted by William C. Roberts, MD, pathologist and executive director of the Baylor Scott & White Heart and Vascular Institute, editor-in-chief of The American Journal of Cardiology and Baylor Heart University Medical Center transplants Proceedings, and dean of the A. Webb Roberts Center for Continuing Medical Education, the program has reunited more than 100 transplant patients with their former heart while serving as a follow-up and educational platform on ways to care for their new one. (FY19) The most heart transplants in the state of Texas 50 The most heart transplants in the state of Texas Clinical trials Baylor University Medical Center’s heart transplantation team continues to notice the medical community’s increasing interest in the program’s growth and variety of cases as well as a robust research initiative. Acceptance of high-risk patients who have been declined by other transplant programs Heart transplants ALL IN: Targeting Inflammation and Alloimmunity in Heart Transplant Recipients with Tocilizumab 50 This is a phase 2, prospective, multi-center, randomized, placebo- controlled clinical trial. The primary objective (FY19) is to assess the efficacy of Acceptance of The most heart Tocilizumab (Actemra) on post-transplant outcomes. The drug, currently high-risk patients transplants in the FDA approved for rheumatologic conditions, is hypothesized who have been state of Texas to improve post-transplant survival rate by reducing incidence of rejection, donor- declined by other transplant specific antibodies, and hemodynamic compromise. Principal Investigator: programs Shelley Hall, MD, FACC, FHFSA TROJAN-C: Transplant of Redeemed Organs by Judicious Administration of New Direct-Acting Antivirals for Hepatitis-C Heart Recipients This phase 2, multi-center, open-label study will evaluate the safety and efficacy of utilizing HCV-positive donors for heart transplant in HCV-negative recipients treated with sofosbuvir 400 mg / velpatasvir 100 mg (Epclusa ® ). The primary objective is to increase the number of viable hearts that can be used for transplant, since drugs are available to treat HCV with minimal side effects. Principal Investigators: Shelley Hall, MD, FACC, FHFSA, and Roger Gottlieb, MD, PhD, FACC For complete inclusion and exclusion criteria for these, please email Amanda Doss, study coordinator, at [email protected]. Collaborative relationships with other transplant centers and heart failure centers, which enable dual listing at two or more centers, reducing the wait time for transplant candidates Heart transplants Acceptance of high-risk patients who have been declined by other transplant programs Collaborative relationships with other transplant centers and heart failure centers, which enable dual listing at two or more centers, reducing the wait time for transplant candidates Heart-to-Heart Program 45